Home > PJ > News / Daily News

Return to PJ Online Home Page
The Pharmaceutical Journal Vol 267 No 7155 p3-8
July 7, 2001

News summary


Pharmacists tackle teenage pregnancy

PHARMACISTS in East Kent are tackling the problem of teenage pregnancy through the introduction of a patient group direction to supply emergency hormonal contraception. Under the PGD, launched on 2 July, women aged below 20 years can obtain Levonelle-2 free from designated pharmacies.

Amanda Harrison, teenage pregnancy co-ordinator, East Kent Health Authority, said that the PGD differed from others for EHC in that it is targeted specifically at young people. A local media campaign to promote the service will begin on 9 July and, in the long term, this might include promotion through schools.

Since the introduction of over-the-counter Levonelle-2, many pharmacists have noted that it tends to be purchased by older women. The East Kent PGD aims to encourage younger women to access emergency contraception through the pharmacy. “The PGD allows the involvement of another health care professional in getting services to young people,” said Ms Harrison. “It makes the most of pharmacists’ skills and their accessibility,” she added.

The inclusion criterion for the East Kent PGD is: “Women below the age of 20 presenting at the pharmacy within 72 hours of the earliest episode of unprotected sexual intercourse.” It notes that in exceptional circumstances, women aged over 20 years can be supplied with Levonelle-2 if they are unable to obtain a supply from another source before the 72 hours expires.

In order to make a supply to a patient who appears to be under 16 years of age, the pharmacist must determine that the patient is Gillick competent (see Panel). If the patient is judged not to be Gillick competent, the pharmacist should not make a supply but refer the patient to a family planning doctor or general practitioner.

If Levonelle-2 is supplied, the pharmacist should advise the patient to have a follow-up appointment with a family planning clinic or GP after three or four weeks to ensure that the EHC has worked and to discuss on-going contraception.

Patients supplied with Levonelle-2 are given an information sheet about the treatment including advice about what to do if they vomit after taking a tablet. Part of the consultation also involves a discussion about ongoing contraception and sexually transmitted diseases, including information about the availability of local family planning clinics and genitourinary medicine clinics. Every patient who accesses the service, regardless of whether or not they are supplied EHC, is given a supply of condoms to address the potential risk of STDs.

Four or five pharmacies in each primary care group across East Kent are participating in the PGD. Pharmacies that are not involved will give the telephone number of an information line to patients that will inform them of the nearest participating pharmacy. All participating pharmacists have received training in issuing EHC including completing a Centre for Pharmacy Postgraduate Education package and attending a training course. In addition, each pharmacist has been visited by a PCG pharmacist to ensure they are happy with the service arrangements. Training must be updated every two years.

Pharmacists must carry out each consultation themselves and make records of every consultation and its outcome. Records have to be kept for eight years if the client is believed to be over 16 years or until the client’s 26th birthday if they are believed to be under 16 years. Pharmacists are paid a fee of £10 by the health authority for each consultation, regardless of whether or not Levonelle-2 is supplied, and are reimbursed for the cost of the drug. To claim payment, pharmacists must submit monitoring forms that include information about who is using the services, why and the outcomes of consultations. Patients do not need to give their name, and data are assessed according to the patient’s locality and date of birth if it has been obtained.

Gillick competence

  • Ask if the patient understands the potential risks and benefits of treatment and advice given
  • Ask if the patient will continue to have intercourse without contraception
  • Assess whether the patient’s physical or mental health will suffer if they do not receive contraceptive advice or treatment
  • Discuss the value of parental support and encourage the patient to inform parents or carers about the consultation while assuring them that confidentiality will be maintained
  • Assess whether it is in the patient’s best interests to provide contraceptive advice or treatment without parental consent

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal